The human cardiovascular system is permanently generating mechanical forces enabling its physiological hemodynamic function. Therefore, our heart and all blood vessels are continuously exposed to significant biomechanical stress.
Adverse biomechanical forces significantly influence onset and progression of many cardiovascular diseases.
At Angiolutions, we understand that sufficient biomechanical organ protection is key to the prevention and treatment of numerous cardiovascular diseases. Following this philosophy, we combine latest medical, biophysical, and molecular research with state-of-the art engineering to create novel mechano-protective devices and realize truly innovative treatment strategies for millions of cardiovascular patients in need.
Angiolutions’ leadership team: Co-founders and Co-CEOs Dr. Uwe Raaz & Dr. Isabel N. Schellinger and Chief Business Officer Marius Rummel. Together, they lead a diverse, interdisciplinary team that is complemented by a board of industry veterans, top clinicians and leading researchers.
receive update emails a few times a year
Please leave your message here